This archived document is no longer being reviewed through the CLSI Consensus Document Development Process. However, this document is technically valid as of September 2016. Because of its value to the laboratory community, it is being retained in CLSI’s library.

**H58-A**

**Platelet Function Testing by Aggregometry; Approved Guideline**

This document provides concrete, standard procedures for using aggregometry to assess platelet function in patient specimens with the intent to achieve greater uniformity of results.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.
Clinical and Laboratory Standards Institute

Setting the standard for quality in medical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement, but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advancements in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential, and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

Appeals Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeals, documented in the CLSI Standards Development Policies and Processes, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute
950 West Valley Road, Suite 2500
Wayne, PA 19087 USA
P: +1.610.688.0100
F: +1.610.688.0700
www.clsi.org
standard@clsi.org
Platelet Function Testing by Aggregometry; Approved Guideline

Volume 28  Number 31

Douglas J. Christie, PhD, FAHA, Chairholder
Thrity Avari, MS
Leonthena R. Carrington, MBA, MT(ASCP)
Eli Cohen, PhD
Barbara A. DeBiase
Paul Harrison, PhD, FRCPath
Thomas S. Kickler, MD
Kandice Kottke-Marchant, MD, PhD
Marlies Ledford-Kraemer, MBA, BS, MT(ASCP)SH
Margaret L. Rand, PhD
Alvin H. Schmaier, MD
Melanie McCabe White

Abstract

Clinical and Laboratory Standards Institute document H58-A—Platelet Function Testing by Aggregometry: Approved Guideline provides concrete, standard procedures for using aggregometry to assess platelet function in patient specimens and samples, with the intent to achieve greater uniformity of results by laboratories following these guidelines. Descriptions of light transmission aggregometry, whole blood impedance aggregometry, and shear-flow technologies are provided so both long-time and new users may establish consistent, reproducible platelet function testing programs in their laboratories.


The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document, because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org. If your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: customerservice@clsi.org; Website: www.clsi.org.
Copyright ©2008 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, companion product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to permissions@clsi.org.

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedure manual at a single site. To request permission to use this publication in any other manner, e-mail permissions@clsi.org.

Suggested Citation


Previous Edition:
June 2007

Archived:
September 2016

ISSN 0273-3099
## Contents

Abstract .................................................................................................................................................... i  
Committee Membership ........................................................................................................................ iii  
Foreword .............................................................................................................................................. vii  

1 Scope .......................................................................................................................................... 1  
2 Introduction ................................................................................................................................ 1  
3 Standard Precautions .................................................................................................................. 1  
4 Terminology ............................................................................................................................... 1  
   4.1 A Note on Terminology ................................................................................................ 1  
   4.2 Definitions ................................................................................................................... . 2  
   4.3 Abbreviations/Acronyms .............................................................................................. 5  
5 Specimen Collection and Processing ......................................................................................... 5  
   5.1 Patient Requirements Before Collection ....................................................................... 5  
   5.2 Specimen Collection ..................................................................................................... 6  
   5.3 Specimen Transport ...................................................................................................... 8  
6 Light Transmission Aggregometry ............................................................................................ 8  
   6.1 Introduction/Principle ................................................................................................... 8  
   6.2 Preexamination Information ......................................................................................... 9  
   6.3 Performance of Light Transmission Platelet Aggregation .......................................... 12  
   6.4 Result Analysis: Light Transmission Aggregation ..................................................... 15  
7 Whole Blood Impedance Aggregometry ................................................................................. 17  
   7.1 Introduction/Principle ................................................................................................. 17  
   7.2 Preexamination Information ....................................................................................... 17  
   7.3 Performance of Impedance Aggregation .................................................................... 18  
   7.4 Result Analysis: Whole Blood Impedance Aggregation and Luminescence .............. 19  
8 Flow and High Shear Devices .................................................................................................. 21  
   8.1 Introduction/Principle ................................................................................................. 21  
   8.2 Preexamination Information ....................................................................................... 21  
   8.3 Performance of High Shear Platelet Function Testing ................................................ 22  
   8.4 Result Analysis: Flow and Shear Devices .................................................................. 22  
9 Quality Assurance and Quality Control ................................................................................... 22  
   9.1 General ........................................................................................................................ 22  
   9.2 Proficiency Testing ........................................................................................................ 23  
   9.3 Establishment of Reference Intervals ............................................................................ 23  
   9.4 Quality Control Concerns ............................................................................................. 24  
   9.5 Specific Details for Light Transmission Aggregometry ................................................ 24  
   9.6 Specific Details for Lumiaggregometry ........................................................................ 24  
   9.7 Specific Details for Whole Blood Aggregometry ....................................................... 25  
   9.8 Specific Details for Flow and High Shear Devices....................................................... 25  
References ............................................................................................................................................. 26
Contents (Continued)

Appendix A. Products Affecting Platelet Function............................................................................. 31

Appendix B. Amount of Anticoagulant Solution/Volume of Blood at Different Packed Cell Volume Values.......................................................................................................................... 32

Summary of Delegate Comments and Committee Responses................................................................. 33

The Quality Management System Approach .......................................................................................... 42

Related CLSI Reference Materials ....................................................................................................... 43
Foreword

Platelets play a vital role in hemorrhagic, thrombotic, and vascular ischemic disorders. Antiplatelet therapy (APT) is regarded as “the cornerstone of treatment” for various coronary conditions,1 giving dramatic rise to the introduction of new antiplatelet drugs. This in turn has increased the interest among clinicians and laboratorians to use various tests of platelet function. One such method is platelet aggregometry, a common technology that has been part of clinical laboratory practice for over 40 years. Yet, surprisingly, platelet aggregometry has largely been performed without globally accepted performance standards. Consequently, customized procedures and reagents are frequently used, often making it difficult to obtain consistent results.

This guideline provides concrete, standard procedures for using aggregometry to assess platelet function in patient specimens and samples with the intent to achieve greater uniformity of results by laboratories following these guidelines. Descriptions of light transmission aggregometry (LTA), whole blood impedance aggregometry, and shear-flow technologies are provided so both long-time and new users may establish consistent, reproducible platelet function testing programs in their laboratories. Laboratories are advised to consult the instrument manufacturer regarding country-specific registration and/or clearance, eg, US Food and Drug Administration 510(k) clearance, CE mark.

Key Words

Antiplatelet therapy (APT), impedance aggregometry, light transmission aggregometry (LTA), low and high shear, platelet activation, platelet aggregation, platelet function testing
Platelet Function Testing by Aggregometry; Approved Guideline

1 Scope

This guideline specifies requirements/recommendations for specimen collection, preexamination considerations, patient preparation, sample processing, testing, result analysis, and quality control (QC) in relation to platelet function testing by aggregometry using light transmission aggregometry (LTA), whole blood impedance aggregometry as well as low and high shear technologies. It covers anticoagulants, specimen storage and transport temperatures, sample selection for various methodologies, establishment of reference intervals, result reporting, result analysis, assay validation, and troubleshooting. The intended users of this guideline are clinicians, hospital and reference laboratorians, manufacturers, and regulatory agencies. This guideline is not intended for use with global hemostasis, platelet counting, flow cytometry, home testing, point-of-care, or research systems. This guideline does not address therapeutic guidance or interpretive guidelines.

2 Introduction

Platelet function testing has been a part of clinical laboratory practice since early in the 20th century. Hundreds of publications have defined healthy and pathologic platelet activity using numerous methodologies, such as the in vivo bleeding time, platelet aggregometry techniques, measurement of granular content and release, assessment of membrane surface markers, evaluation of signaling pathways, and in vivo platelet survival. Yet, despite this vast wealth of information, no clear direction exists to guide setting minimum performance standards among laboratories performing platelet function testing. Establishing such a path is critical, given the role of platelets in both hemorrhagic and thrombotic conditions and the rising significance of antiplatelet therapy (APT) in controlling platelet function across a broad spectrum of vascular disorders. The goal of this guideline is to set minimum requirements for the performance of platelet function testing when using LTA, whole blood impedance aggregometry, and shear-flow technologies.

3 Standard Precautions

Because it is often impossible to know what isolates or specimens might be infectious, all patient and laboratory specimens are treated as infectious and handled according to “standard precautions.” Standard precautions are guidelines that combine the major features of “universal precautions and body substance isolation” practices. Standard precautions cover the transmission of all infectious agents and thus are more comprehensive than universal precautions, which are intended to apply only to transmission of blood-borne pathogens. Standard and universal precaution guidelines are available from the US Centers for Disease Control and Prevention. For specific precautions for preventing the laboratory transmission of all infectious agents from laboratory instruments and materials and for recommendations for the management of exposure to all infectious disease, refer to CLSI document M29.

4 Terminology

4.1 A Note on Terminology

CLSI, as a global leader in standardization, is firmly committed to achieving global harmonization wherever possible. Harmonization is a process of recognizing, understanding, and explaining differences while taking steps to achieve worldwide uniformity. CLSI recognizes that medical conventions in the global metrological community have evolved differently in the United States, Europe, and elsewhere; that these differences are reflected in CLSI, ISO, and CEN documents; and that legally required use of terms, regional usage, and different consensus timelines are all challenges to harmonization. In light of this,
CLSI recognizes that harmonization of terms facilitates the global application of standards and deserves immediate attention. Implementation of this policy must be an evolutionary and educational process that begins with new projects and revisions of existing documents.

In order to align the usage of terminology in this document with that of ISO, the term *accuracy*, in its metrological sense, refers to the closeness of agreement between a measured quantity value and a true quantity value of a measurand, and comprises both random and systematic effects. *Precision* is defined as the “closeness of agreement between independent test/measurement results obtained under stipulated conditions.” As such, it cannot have a numerical value, but may be determined qualitatively as high, medium, or low.

The term *measurand* (quantity intended to be measured) is used in combination with the term *analyte* (component represented in the name of a measurable quantity) when its use relates to a biological fluid/matrix.

Users of H58-A should understand, however, that the fundamental meanings of the terms are identical in many cases, and to facilitate understanding, terms are defined in the Definitions section of this guideline.

All terms and definitions will be reviewed again for consistency with international use, and revised appropriately during the next scheduled revision of this document.

### 4.2 Definitions

**accuracy (of measurement)** – closeness of agreement between a measured quantity value and a true quantity value of a measurand (VIM07).\(^4\)

**activation** – when referring to platelets, a series of processes and events that change a discoid platelet into a spiny, spiculated entity with extension of pseudopodia that results in the initiation of signal transduction.

**adhesion** – the process by which platelets attach to surfaces or surface-bound proteins by certain glycoproteins, selectins, and integrins.

**aggregation** – platelet clumping, largely mediated by fibrinogen or von Willebrand factor binding to the platelet receptor, GPIIb/IIIa (integrin \(\alpha_{IIb}\beta_3\)), following activation of intact platelets by agonists or shear stress.

**agonist** – a substance or protein that can stimulate platelet activation (eg, collagen, adenosine diphosphate [ADP], epinephrine, thrombin, arachidonic acid, ristocetin).

**analyte** – component represented in the name of a measurable quantity (ISO 17511)\(^5\); **NOTE 1:** In the type of quantity “mass of protein in 24-hour urine,” “protein” is the analyte. In “amount of substance of glucose in plasma,” “glucose” is the analyte. In both cases, the long phrase represents the *measurand* (ISO 17511)\(^5\); **NOTE 2:** In the type of quantity “catalytic concentration of lactate dehydrogenase isoenzyme 1 in plasma,” “lactate dehydrogenase isoenzyme 1” is the analyte (ISO 18153).\(^6\)

**anticoagulant** – an agent, natural or pharmacological, that inhibits clotting of blood or plasma.

**blank** – sample that does not contain the analyte of interest, or has a concentration at least an order of magnitude less than the lowest level of interest; **NOTE:** In the context of this document, in most cases, this is platelet-poor plasma (PPP).
The Quality Management System Approach

Clinical and Laboratory Standards Institute (CLSI) subscribes to a quality management system approach in the development of standards and guidelines, which facilitates project management; defines a document structure via a template; and provides a process to identify needed documents. The approach is based on the model presented in the most current edition of CLSI/NCCLS document HS01—A Quality Management System Model for Health Care. The quality management system approach applies a core set of “quality system essentials” (QSEs), basic to any organization, to all operations in any health care service’s path of workflow (ie, operational aspects that define how a particular product or service is provided). The QSEs provide the framework for delivery of any type of product or service, serving as a manager’s guide. The QSEs are:

- Documents & Records
- Equipment
- Organization
- Personnel
- Purchasing & Inventory
- Information Management
- Process Improvement
- Process Control
- Occurrence Management
- Assessments—External & Internal
- Customer Service
- Facilities & Safety
- Process Improvement
- Facilities & Safety

H58-A addresses the QSEs indicated by an “X.” For a description of the other documents listed in the grid, please refer to the Related CLSI Reference Materials section on the following page.

Path of Workflow

A path of workflow is the description of the necessary steps to deliver the particular product or service that the organization or entity provides. For example, CLSI/NCCLS document GP26—Application of a Quality Management System Model for Laboratory Services defines a clinical laboratory path of workflow, which consists of three sequential processes: preexamination, examination, and postexamination. All clinical laboratories follow these processes to deliver the laboratory’s services, namely quality laboratory information.

H58-A addresses the clinical laboratory path of workflow steps indicated by an “X.” For a description of the other documents listed in the grid, please refer to the Related CLSI Reference Materials section on the following page.

Adapted from CLSI/NCCLS document HS01—A Quality Management System Model for Health Care.
Related CLSI Reference Materials*


GP29-A2  Assessment of Laboratory Tests When Proficiency Testing Is Not Available; Approved Guideline—Second Edition (2008). This document offers methods to assess test performance when proficiency testing (PT) is not available; these methods include examples with statistical analyses. This document is intended for use by laboratory managers and testing personnel in traditional clinical laboratories as well as in point-of-care and bedside testing environments.

H01-A5  Tubes and Additives for Venous Blood Specimen Collection; Approved Standard—Fifth Edition (2003). This document contains requirements for venous blood collection tubes and additives, including technical descriptions of ethylenediaminetetraacetic acid (EDTA), sodium citrate, and heparin compounds used in blood collection devices.


H18-A3  Procedures for the Handling and Processing of Blood Specimens; Approved Guideline—Third Edition (2004). This document includes criteria for preparing an optimal serum or plasma sample and for the devices used to process blood specimens.

H21-A5  Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays and Molecular Hemostasis Assays; Approved Guideline—Fifth Edition (2008). This document provides procedures for collecting, transporting, and storing blood; processing blood specimens; storing plasma for coagulation testing; and general recommendations for performing the tests.

M29-A3  Protection of Laboratory Workers From Occupationally Acquired Infections; Approved Guideline—Third Edition (2005). Based on US regulations, this document provides guidance on the risk of transmission of infectious agents by aerosols, droplets, blood, and body substances in a laboratory setting; specific precautions for preventing the laboratory transmission of microbial infection from laboratory instruments and materials; and recommendations for the management of exposure to infectious agents.

* Proposed-level documents are being advanced through the Clinical and Laboratory Standards Institute consensus process; therefore, readers should refer to the most current editions.
Explore the Latest Offerings From CLSI!

As we continue to set the global standard for quality in laboratory testing, we are adding products and programs to bring even more value to our members and customers.

By becoming a CLSI member, your laboratory will join 1,600+ other influential organizations all working together to further CLSI’s efforts to improve health care outcomes. You can play an active role in raising global laboratory testing standards—in your laboratory, and around the world.

Find out which membership option is best for you at www.clsi.org/membership.

Find what your laboratory needs to succeed! CLSI U provides convenient, cost-effective continuing education and training resources to help you advance your professional development. We have a variety of easy-to-use, online educational resources that make eLearning stress-free and convenient for you and your staff.

See our current educational offerings at www.clsi.org/education.

When laboratory testing quality is critical, standards are needed and there is no time to waste. eCLIPSE™ Ultimate Access, our cloud-based online portal of the complete library of CLSI standards, makes it easy to quickly find the CLSI resources you need.

Learn more and purchase eCLIPSE at clsi.org/eCLIPSE.

For more information, visit www.clsi.org today.